Why is the Paradigm share price surging 7% today?

The biopharmaceutical company is partnering with the National Football League's Alumni Health service.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Paradigm shares lift more than 7% to $1.125 on Wednesday
  • The company entered into a research partnership to inform NFL Alumni members about osteoarthritis (OA)
  • NFL Alumni Health will pass on information about Paradigm’s role in developing a treatment for pain and dysfunction associated with knee osteoarthritis

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is in the green on Wednesday following the company's latest announcement.

At the time of writing, the biopharmaceutical company's shares are fetching at $1.055 each, up 0.48%. Earlier in the session, the company's share price hit $1.125, a surge of more than 7%.

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.

Image source: Getty Images

What did Paradigm announce?

According to this morning's announcement, Paradigm advised that it has entered into a corporate partnership with the US's National Football League Alumni Health (NFLAH).

Under the collaboration, NFL Alumni Association (NFLAA) members will be informed about osteoarthritis (OA) and current treatment options. Furthermore, information will be provided to interested participants about actively enrolling in OA clinical trials throughout the United States.

The NFL's Alumni Association has more than 10,000 members which consist of former NFL players, coaches, executives, spouses, cheerleaders, and associate members.

Paradigm is seeking to unlock the potential benefits of pentosan polysulfate sodium (PPS) for the treatment of musculoskeletal disorders.

Paradigm's leading drug candidate Zilosul is used to treat OA, a progressive disease that affects more than 240 million people globally.

The injectable PPS treatment has previously shown improvements in pain reduction, joint function, and the prevention of cartilage damaging joints.

It seems investors are excited about the company expanding its access program for the potential treatment of OA, sending the Paradigm share price higher.

Paradigm CEO Marco Polizzi commented:

Having followed the progress of the expanded access program participants and hearing first-hand the positive impact Zilosul has had on their lives, Paradigm is honoured to be able to continue to work with NFL Alumni members to inform them of the onset and progression of osteoarthritis and Paradigm's clinical progress through phase 3 as we strive to bring Zilosul to commercialisation for the millions suffering from the debilitating effects of OA.

About the Paradigm share price

The Paradigm share price is down 48% in the past 12 months with most of these losses in the year to date.

The company's shares reached a 52-week low of 85.5 cents a share in late June before rebounding over the past two weeks.

Based on the current share price, Paradigm has a market capitalisation of around $236 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »

Woman with a concerned look on her face holding a credit card and smartphone.
Healthcare Shares

What on earth's going on with the CSL share price?

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more…

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These ASX healthcare stocks are set to thrive as the population ages

A powerful demographic tailwind, but can they execute?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This drug developer could have huge upside, brokers say

Gains of more than 100% are not off the cards apparently.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Four ASX healthcare stocks which are looking cheap

These companies could be just what the doctor ordered.

Read more »

Two health workers taking a break.
Healthcare Shares

Bell Potter is tipping this exciting ASX healthcare stock to rise 80%

An important clinical trial announcement is good news for this healthcare stock.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

Is this one of the best ASX 200 stocks money can buy?

High margins, strong growth, and global expansion have helped this ASX company stand out to me.

Read more »